A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of ABBV-927 and ABBV-181, an Immunotherapy, in Subjects With Advanced Solid Tumors
Latest Information Update: 24 Jun 2024
At a glance
- Drugs Budigalimab (Primary) ; Giloralimab (Primary) ; Giloralimab (Primary)
- Indications Head and neck cancer; Non-small cell lung cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; Pharmacokinetics
- Sponsors AbbVie
- 18 Jun 2024 Planned End Date changed from 29 Mar 2024 to 30 Mar 2025.
- 18 Jun 2024 Planned primary completion date changed from 29 Mar 2024 to 30 Mar 2025.
- 19 Jan 2024 Planned End Date changed from 10 Feb 2024 to 29 Mar 2024.